Answers are grounded in this paper and cite their sources.
Review evaluates bioanalytical methods for rivastigmine in biological matrices, highlighting implications for monitoring therapy effectiveness.
Rivastigmine is a cholinesterase inhibitor widely used for the symptomatic treatment of Alzheimer’s disease and Parkinson’s disease dementia. Its therapeutic action occurs primarily in the central nervous system, making brain distribution a critical determinant of clinical efficacy. After administration, rivastigmine is rapidly absorbed, exhibits a short elimination half-life, and readily crosses the blood–brain barrier. Consequently, plasma concentrations are very low and decline rapidly, and circulating levels may not directly reflect drug exposure at the target site. These pharmacokinetic characteristics support the evaluation of bioanalytical methods and their potential relevance to therapeutic drug monitoring in specific contexts. This review evaluates published bioanalytical methods for rivastigmine determination and their relevance to pharmacokinetic studies and therapeutic drug monitoring. Eleven validated studies (2003–2026) were analyzed, including analyses in human plasma, animal plasma, brain tissue, and urine. Plasma is primarily used to assess systemic exposure, while brain tissue confirms central distribution, and urine supports excretion profiling. However, endogenous proteins and phospholipids frequently cause matrix effects, necessitating sample preparation techniques such as protein precipitation, liquid–liquid extraction, and solid-phase extraction. Across studies, liquid chromatography–tandem mass spectrometry (LC–MS/MS) has become the dominant analytical approach due to its superior sensitivity, enabling picogram-level quantification that supports reliable pharmacokinetic profiling at low concentrations. Therapeutic drug monitoring has been discussed in relation to interindividual variability and concentration-related cholinergic adverse effects. However, its clinical applicability remains context-dependent and not yet fully established. Overall, rivastigmine biodistribution defines bioanalytical requirements, and the selection of analytical methods should be aligned with specific study objectives. Highly sensitive chromatographic techniques are advantageous for characterizing low systemic concentrations, while other validated methods may remain appropriate depending on the required detection limits and research context.
No takes yet. Share an insight, caveat, or question.
Nababan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: